Exact Sciences Corporatio... (EXAS)

Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.

Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value investor. The Ark Invest co-founder, CEO, and chief investment officer is often a...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Exact Sciences Corp. EXAS on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Derek Leckow - Vice President of Inves...

Exact Sciences (EXAS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.09 per share a year ago.

Exact Sciences (EXAS) Q2 Revenue Up 16%

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for...